Medical device manufacturers are expanding the scope of wearable biosensors beyond diabetes management into broader metabolic health monitoring. Phase III clinical trials are currently evaluating multi-analyte continuous sensors.
Diagnostic Accuracy
Preliminary trial results indicate that real-time tracking of lactate and cortisol levels alongside glucose offers a 35 percent improvement in early detection of acute metabolic stress. Regulatory submissions are projected for early next year.